0001209191-19-000270.txt : 20190102 0001209191-19-000270.hdr.sgml : 20190102 20190102162022 ACCESSION NUMBER: 0001209191-19-000270 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181231 FILED AS OF DATE: 20190102 DATE AS OF CHANGE: 20190102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MARLETT CHRISTOPHER A CENTRAL INDEX KEY: 0000897744 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38327 FILM NUMBER: 19501918 MAIL ADDRESS: STREET 1: 100 WILSHIRE BLVD CITY: SANTA MONICA STATE: CA ZIP: 90401 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cue Biopharma, Inc. CENTRAL INDEX KEY: 0001645460 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473324577 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 675 W. KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-949-2680 MAIL ADDRESS: STREET 1: 675 W. KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Imagen Biopharma, Inc. DATE OF NAME CHANGE: 20150617 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-12-31 0 0001645460 Cue Biopharma, Inc. CUE 0000897744 MARLETT CHRISTOPHER A 2425 CEDAR SPRINGS ROAD DALLAS TX 75201 1 0 0 0 Common Stock 2018-12-31 4 P 0 18521 4.64 A 89602 I See footnote Common Stock 9000 D Common Stock 1017973 I See footnote The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.56 to $4.70, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee. The record owner of these securities is MDB Capital Group, LLC ("MDB"). The reporting person is the Chief Executive Officer of MDB. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein and inclusion of these securities in the report shall not be an admission of beneficial ownership for purposes of Section 16 or any other purposes. /s/ Christopher Marlett by Mark R. Busch, attorney-in-fact 2019-01-02